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Introduction: Autologous mesenchymal stem cell (MSC) injection into naturally-occurring equine tendon injuries
has been shown to be safe and efficacious and protocols inform translation of the technique into humans. Efficient
transfer of cells from the laboratory into tissue requires well-validated transport and implantation techniques.
Methods: Cell viability in a range of media was determined over 72 hours and after injection through a 19G,
21G or 23G needle. Viability, proliferation and apoptosis were analysed using TrypanBlue, alamarBlue® and
AnnexinV assays.
Results: Cell viability was similar in all re-suspension media following 24 hour storage, however cell death was
most rapid in bone marrow aspirate, platelet-rich plasma and serum after longer storage. Cryogenic media exhibited
greatest viability regardless of storage time. Cell proliferation after 24 and 72 hour storage was similar for all media,
except after 24 hours in serum wherein proliferation was enhanced. MSC tri-lineage differentiation and viability did
not significantly change when extruded through 19G, 21G or 23G needles, but 21G and 23G needles significantly
increased apoptotic cells compared to 19G and non-injected controls. All gauges induced a decrease in metabolic
activity immediately post-injection but cells recovered by 2 hours.
Conclusions: These data indicate storage and injection influence viability and subsequent cell behaviour and
provide recommendations for MSC therapy that implantation of cells should occur within 24 hours of recovery
from culture, using larger needle bores.Introduction
The use of autologous mesenchymal stem cells (MSCs)
derived from bone marrow to enhance tendon lesion
repair is supported by a growing body of evidence from
both experimental and clinical studies [1-5]. In the ten-
don, influx of a local subpopulation of precursor cells is
believed to provide intrinsic post-injury repair [6]. How-
ever, these cells appear to be largely derived from peri-
tendinous origins such as the paratenon [7] and result in
fibrous repair with mechanical, structural and compos-
itional differences from normal tendon. In an attempt to
modify the repair towards regeneration, enhancing the
small numbers of endogenous MSCs by implantation of
large numbers of autologous, culture-expanded MSCs
derived from donor tissue such as bone marrow, has
been proposed. This hypothesis has been supported by* Correspondence: jdudhia@rvc.ac.uk
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unless otherwise stated.positive results in experimental laboratory animal
models of Achilles and patellar tendon injury [4,5].
However, many laboratory animal models of induced in-
jury have limited relevance to the human disease [8].
Horses, in contrast, suffer naturally-occurring flexor
tendon injury with many similarities to human Achilles
tendinopathy, making the horse a useful translational
model for stem cell therapies. In recent years, a method-
ology for isolation, expansion and injection of autolo-
gous bone marrow-derived MSCs into lesions of the
equine superficial digital flexor tendon has been widely
accepted into clinical practice for the treatment of this
disease [9]. Optimisation of cell-based therapies would
ideally require accurate delivery to the target area
without significant loss of cellular function or viability
[10,11], although a recent study established that only
24% of injected MSCs were retained at the site of injury
after 24 hours [12]. Factors that may influence this poor
cell retention include reduced cell viability followingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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process of intralesional injection.
The current, commercial application of MSCs involves
laboratory proliferation to achieve sufficient cells that
then are either transported overnight, at 4 to 8°C, in
autologous bone marrow aspirate (BMA) at a concentra-
tion of 5 × 106 cells/ml [1] or are frozen [13]. The former
technique was designed to achieve a fully autologous
preparation that can be immediately injected, while the
second requires thawing before implantation. These pro-
tocols, however, have not been tested in comparison
with each other, or with other potential transport media.
The first aim of this study was therefore to evaluate cell
survival in different transport media.
Once the cells arrive at the clinic, they are injected
under ultrasound guidance directly into the lesion within
the recipient tendon. The disrupted central area of the
tendon provides a cavity into which the cells are slowly
injected with minimal injection pressure. Cells respond
to external mechanical influences that affect their survival,
growth and differentiation. Inappropriate stimulation of
signalling pathways can lead to premature apoptosis, a
complex cascade of events leading to the final demise of
the cell [14]. The injection process could therefore poten-
tially influence post-injection cell survival and metabolism.
The most likely cause of cellular damage during injection
is sheer stress, caused by the turbulent flow of fluid at the
outer edges of the flow channel, where viscous fluid is in
contact with the channel walls. Sheer stress is influenced
by pressure, cross-sectional area and length of the channel
[15], and by sudden changes in geometry, such as the
rapid tapering of the vessel diameter from syringe to nee-
dle hub [10]. The surface marker phenotype and differen-
tiation ability of rat and human MSCs were reportedly
unaffected immediately following injection through cathe-
ters and needles at clinically relevant sizes and flow rates
[10,16], although a significant reduction in viability was
observed for all catheters 24 hours after infusion. In con-
trast, another study demonstrated that longer and thinner
cannulae were damaging to cells [17]. Other studies inves-
tigating cell printing methods to deposit cells in tissue
scaffolds demonstrated significant loss of viability with
increasing dispensing pressure and reducing nozzle size
[18,19] and suggested that a recovery period was necessary
following injection. The technique developed for clinical
use in the horse, which has direct relevance to human
treatment, utilises a 2 ml syringe and hypodermic nee-
dle. A second aim of the present study was therefore to
investigate the influence of needle size in this system
on both cell viability and the potential delayed effects
of injection.
This study demonstrates that transport media but not
needle size influenced cell viability, but both had delayed
effects on cell metabolism and apoptosis.Materials and methods
Isolation of mesenchymal stem cells
Ethical approval for the collection of bone marrow
aspirates and blood was received from the Ethics and
Welfare Committee at the Royal Veterinary College
(URN 2013 1230R 2005). No horses were euthanased for
the sole purpose of obtaining tissues for this study. Bone
marrow-derived MSCs (n = 3) were obtained and ex-
panded as described previously [9] and P0 to P2 passage
cells were stored in Bambanker™ cell freezing medium
(Anachem, Luton, UK) in liquid nitrogen until use. For
experiments, cells were seeded in D10 medium (Dulbec-
co’s modified Eagle’s medium, supplemented with foetal
calf serum (10% v/v), 100 U/ml penicillin, and 100 U/ml
streptomycin; all from Invitrogen, Paisley, UK) and were
expanded to the required numbers. Cells were then de-
tached from the culture flasks by trypsin–ethylenedi-
amine tetraacetic acid (Sigma-Aldrich, Gillingham, UK)
for storage media and needle gauge experiments.
Effect of storage media
MSCs (2.5 × 106 cells) were resuspended in the test
media at a concentration of 5 × 106 cells/ml and trans-
ferred to 1 ml cryotube vials (PAA, Yeovil, UK). Resus-
pension media were as follows: D10; allogenic BMA;
hyaluronic acid (as sodium hyaluronate at a concentra-
tion of 10 mg/ml in isotonic sodium chloride–phosphate
buffer, pH 7.0; Bayer PLC, Newbury, UK); allogenic
plasma (heparinised) and allogenic serum obtained by
routine venipuncture from a horse free of systemic
disease; isotonic saline (Dechra Pharmaceuticals,
Northwich, UK); allogenic platelet-rich plasma (prepared
by routine venipuncture into 3.8% trisodium citrate (ratio
9:1), after which platelets were concentrated by centrifuga-
tion as previously described [20] and the platelet pellet
was resuspended in D10 (2 ml for platelets pellets pre-
pared from 20 ml plasma)); and cryogenic cell freezing
medium (90% equine serum, 10% dimethyl sulphoxide).
Vials were stored at 4 to 8°C until analysis except for
those containing cell-freezing medium, which were
stored in dry ice (−78°C). Prior to assaying, these vials
were warmed briefly in a 37°C water bath with care to
avoid heating beyond melting point. Cells were thawed
by slow addition (over 90 seconds) of an equal volume
of lactated Ringer’s solution (Dechra Pharmaceuticals)
to the vial. After storage for 12, 24, 48 and 72 hours,
cells for all media were assayed for viability and cell
proliferation as detailed below.
Effect of needle gauge
MSCs were diluted to a final suspension density of 5 ×
106 cells/ml in D10. One millilitre of cell suspension
from each cell line was set aside as a non-injected con-
trol group. One-millilitre aliquots of MSCs were slowly
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needle attached (as is the practice for clinical MSC
injection). Needle sizes of 21G (currently used for MSC
injection), 23G (one gauge smaller) and 19G (one gauge
larger) were used. All needles were 50 mm in length
(Terumo Ltd, Bagshot, UK). The loaded 2 ml syringe
was then fixed concentrically within a 30 ml syringe to
enable mounting into a Flo-Gard GSP syringe pump
(Baxter, Newbury, UK). The extrusion rate was set to
900 ml/hour and the volume (Volume to be Infused) set
at 7.5 ml, which was appropriate to deliver a 1 ml volume
from the 2 ml syringe over 30 seconds to mimic the slow,
steady injection of MSCs applied in clinical practice. Cell
viability, proliferation and apoptosis assays were performed
immediately after extrusion of cells from the needles and
on the non-injected control cells.
Viability assay
The viability of cell suspensions from both the storage
media and needle experiments were determined by mix-
ing 100 μl cell suspension with 100 μl of 0.4% trypan
blue solution (Sigma-Aldrich) for 2 minutes. Cells were
counted using a haemocytometer microchamber under a
light microscope [21].
Cell proliferation assay
To assess the ability of the cells to proliferate following stor-
age in the various storage media, a proliferation assay was
performed using the alamarBlue® assay (AbD Serotec,
Kidlington, UK). Then 5 × 103 cells were seeded in duplicate
into each well of a microtitre plate in D10 and allowed to ad-
here for 24 hours. The media were replaced with 1 ml D10
containing 100 μl alamarBlue® reagent and cells were incu-
bated for a further 4 hours, shielded from light. Then
100 μl aliquots were transferred to a black fluoro-
microtitre plate (SPL LifeSciences, Singapore, UK) and
fluorescence was measured at 570 nm (excitation) and
585 nm (emission) (Infinite M200 PRO fluorometer; Tecan,
UK). The media in the cells was replaced with fresh D10
and the assay was repeated at 24, 48 and 72 hours as above.
Mesenchymal stem cell characterisation
Chondrogenic, adipogenic and osteogenic differentiation
assays were performed and assessed as described previ-
ously [22].
Metabolic activity
Cell suspensions from the needle gauge experiments
were assayed for metabolic activity using the alamarBlue®
reagent. Cells were diluted to a concentration of 2.5 ×
105 cells/ml in D10, and 100 μl alamarBlue® reagent was
added and incubated at 37°C. At 4, 6, 8 and 24 hours,
100 μl aliquots of sample were then measured for fluor-
escence as detailed above. Readings obtained for needleinjected cells were compared with values for the non-
injected control cells.
Apoptosis assay
The Annexin V–fluorescein isothiocyanate enzyme-linked
immunosorbent assay (Cayman Chemical, Ann Arbor, MI,
USA) was used to assess the effect of needle size on induc-
tion of apoptosis. The assay was validated in preliminary as-
says for cross-reactivity of the Annexin V antibody to the
equine antigen using positive inducers of apoptosis. Cells
were treated with staurosporine (500 and 100 nM) and in-
cubated at 37°C for 3 hours or with sodium azide (20 nM)
and incubated at 37°C for 2 hours. Cells were also heated to
45°C for 10 minutes to induce apoptosis. In addition, test
cells were included where 1 ml cells in a 2 ml syringe were
extruded through a 21G needle, and non-injected cells were
suspended in D10 or in fresh allogeneic plasma. The assay
was performed according to the manufacturer’s instructions.
Briefly, staining solutions were prepared in Annexin V bind-
ing buffer (0.01 M HEPES, pH 7.4; 0.14 M NaCl; 2.5 mM
CaCl2) to contain either Annexin V–fluorescein isothio-
cyanate antibody or propidium iodide, and were protected
from direct light. Samples (100 μl containing 500,000 cells)
were washed twice in 1 ml Annexin V binding buffer by
centrifugation at 350 × g and cells were resuspended by gen-
tle agitation in 250 μl of each staining solution. Samples
were wrapped in aluminium foil to protect from direct light
and incubated for 10 minutes at room temperature. Cells
were washed as before and resuspended in 100 μl Annexin
V binding buffer, and 10 μl aliquots were applied to a glass
slide and mounted under a coverslip to visualise by fluores-
cence microscopy (using an Olympus BX61). The number
of cells staining positive for propidium iodide (dead cells)
using a rhodamine filter (excitation 540 nm and emission
570 nm) or Annexin V (cells in early apoptosis) using a
fluorescein filter (excitation 485 nm and emission 535 nm)
were counted. Means of cell counts from six fields of view
per slide were determined at 20× magnification for both
stains and the total cell number under a bright field. Test
groups were analysed at 0, 2, 4 and 24 hours post injection.
The validation experiments confirmed that the Annexin
V antibody (anti-human antibody) cross-reacted with the
equine antigen and revealed that the strongest inducers
of apoptosis were 500 nM staurosporine and injection
through the 19G needle. While all conditions induced
apoptosis, there was no significant difference between any
of the known apoptosis inducers. Comparison of the per-
centage of Annexin V immunofluorescent cells with the
inducers of apoptosis with that of non-injected control
cells in either D10 or fresh plasma revealed a significant
increase in the proportion of early apoptotic cells with all
apoptotic stimuli applied (P < 0.01; Figure 1).There was no
significant difference in the mean total cell number be-
tween test groups, enabling confident comparison of the
Figure 1 Validation of apoptosis in equine mesenchymal stem cells. Representative fluorescence images are shown for cells injected
through a 21G needle, with (a) cell surface Annexin V (fluorescein isothiocyanate) and (b) nuclear propidium iodide staining of cells. (c) Merged
Annexin V and propidium iodide images to distinguish coincidal and noncoincidal staining of cells. Cells in early apoptosis (green and green–red)
and in late apoptosis (red) are present. Original magnification × 100, scale bar = 200 μm. (d) Quantification of apoptotic cells after treatment with
known inducers of apoptosis. Cells injected through a 19G needle in D10 or in plasma are shown together with non-injected controls. D10,
Dulbecco’s modified Eagle’s medium supplemented with 10% foetal bovine serum.
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positive cells calculated as a percentage of total cells.
Statistical analysis
Where descriptive analysis indicated that the data were
not normally distributed, a log transformation was per-
formed to normalise the data prior to analysis. Longitu-
dinal data were analysed using a mixed-effects linear
regression model in PASW (version 18; IBM, Portsmouth,
UK), with Sidak correction. In order to interrogate the re-
lationship between and within the multiple factors on cell
viability or proliferation, statistical analysis was performed
using analysis of variance within a mixed-effects model.
P ≤0.05 was considered significant.
Results
Effect of resuspension media
Cell viability was not significantly different between
any of the storage media at 12 or 24 hours; however,
viability decreased significantly over time (P < 0.001)
and by 72 hours ranged from 25 to 78%, with the mostrapid decline observed for cells suspended in the bio-
logical fluids, BMA, platelet-rich plasma and serum.
Cell viability was greatest at all time points when cells
were frozen in cryogenic medium. There was a signifi-
cant reduction in viability for cells suspended in BMA
in comparison with cells in cryogenic medium at
48 hours (P = 0.027) and 72 hours (P = 0.024) (Figure 2;
Table 1).
Cells stored for 24 hours in saline initially proliferated
significantly faster than those stored in any other media
(P < 0.001 in all comparisons) but there were no signifi-
cant differences in cell proliferation following 72 hours
of storage. Interestingly, proliferation was enhanced at
72 hours compared with 24 hours for cells stored
in BMA, D10, serum, hyaluronic acid and cryogenic
medium, while other storage media showed a decrease
(Figure 3a). Cells stored in all media showed similar
proliferation rates when transferred to standard cul-
ture media (D10) except for those that had been stored
in serum for 24 hours, in which there was a subse-
quently enhanced proliferation rate (Figure 3b,c).
Figure 2 Cell viability measured by trypan blue exclusion assay. Viability of mesenchymal stem cells (n = 3) stored for up to 72 hours in a
range of experimental suspension media are shown. BMA, bone marrow aspirate; D10, Dulbecco’s modified Eagle’s medium supplemented with
10% foetal bovine serum; HA, hyaluronic acid; PRP, platelet-rich plasma.
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Injection of cells did not cause an immediate loss in via-
bility either for different needle gauges (Figure 4) or
when comparing injected and non-injected groups (data
not shown). There was, however, a significant effect of
needle gauge on the proportion of cells staining positive
for Annexin V (early apoptosis) or propidium iodide
(late apoptosis) (P < 0.01; Figure 5a,b). There was a signifi-
cant increase in apoptotic cells when injected through a
21G or 23G needle for both Annexin V (P < 0.01) and pro-
pidium iodide (P < 0.05) compared with non-injected cells,Table 1 Statistical comparison of cell viability over time
in different suspension media
Suspension media P value Suspension media P value
BMA D10 <0.001 D10 Serum 0.021
Serum n/s PRP <0.001
PRP n/s Plasma n/s
Plasma 0.001 HA n/s
HA 0.01 Saline n/s
Saline <0.001 Frozen n/s
Frozen <0.001 Serum PRP n/s
PRP Plasma 0.045 Plasma n/s
HA n/s HA n/s
Saline 0.007 Saline n/s
Frozen <0.001 Frozen 0.001
Plasma HA n/s HA Saline n/s
Saline n/s Frozen n/s
Frozen n/s Saline Frozen n/s
BMA, bone marrow aspirate; D10, Dulbecco’s Modified Eagle Medium
supplemented with 10% foetal bovine serum; HA, hyaluronic acid; n/s,
no significant difference; PRP, platelet-rich plasma.although there was no significant difference between non-
injected cells and those injected through a 19G needle. Fur-
thermore, there was a significant increase in cells staining
positive with Annexin V following injection through the
23G (smallest diameter) needles compared with the 19G
(largest diameter) needles (P = 0.023). Injection through the
21G needle (which is currently recommended for clinical
use) resulted in approximately 9% of the cell population
staining positive for Annexin V immediately post injection.
There was minimal change in the percentage of
Annexin V and propidium iodide-positive cells within
the non-injected group over the 24-hour period. While
Annexin V-positive cells decreased in the 21G and 23G
groups over the 24-hour period, it was interesting to
note that an increased number of positive cells was evi-
dent at 2 hours in the 19G group (Figure 5b), suggesting
delayed induction of apoptosis.
There was a significant decrease in alamarBlue® absorb-
ance for all injected cells when compared with non-
injected cells immediately post injection (P < 0.01),
indicating an adverse effect on cell metabolism, but by
2 hours the injected cells had recovered to control
levels (Figure 5c).
Effect of needle gauge on cell differentiation
MSCs all showed trilineage (osteogenic, adipogenic and
lipogenic) differentiation and injection of cells did not
result in any detectable alteration in differentiation abil-
ity either for different needle gauges or when comparing
injected and non-injected groups (Figure 6).
Discussion
This study has demonstrated significant adverse influences
on MSCs associated with transport and implantation. It is
Figure 3 Cell proliferation measured by alamarBlue® assay for mesenchymal stem cells (n = 3) following storage for 24 or 72 hours in
suspension media. (a) Initial proliferation rates. (b) Change in the proliferation rate with time following storage for 24 hours. (c) Change in the
proliferation rate with time following storage for 72 hours. BMA, bone marrow aspirate; D10, Dulbecco’s modified Eagle’s medium supplemented
with 10% foetal bovine serum; HA, hyaluronic acid; PRP, platelet-rich plasma. alamarBlue® from AbD Serotec (Kidlington, UK).
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plantation technique that minimises these adverse effects
so as to maximise viable cell delivery to the site of injury.
With respect to the selection of transport media, it
would appear that any of the wide array of those tested
would be satisfactory when implantation occurs within
24 hours, as is customary with the clinical supply of
MSCs in the veterinary field. Once cells were suspendedfor longer than 24 hours, viability of cells stored in BMA
was significantly less than if the cells were frozen in
cryogenic medium. Although there is, as yet, no guid-
ance on the storage of MSCs, it has been suggested that
in vitro storage of haematopoietic stem or progenitor
cells should not exceed 2 hours [23]. This suggestion is
impractical both for current equine therapeutic use and
when considering future, commercial applications of MSC
Figure 4 Viability of cells after injection through different gauge needles. Data are shown for viability measured immediately after
injection of mesenchymal stem cells (n =3) in D10 through 19G, 20G or 21G needles. Non-injected control cells are also shown. There
were no significant differences between any of the conditions. D10, Dulbecco’s modified Eagle’s medium supplemented with 10% foetal
bovine serum.
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necessity to transport the cells from a remote licensed facil-
ity to the clinic and our data suggest that up to 24 hours
for transportation is possible without significant detrimen-
tal effects. For transportation periods suspected to be of
greater duration than 24 hours, cells should ideally be fro-
zen, to maximise cell viability. However, the cell suspension
media in which MSCs were frozen is not an ideal carrier
for intralesional injection, and resuspension in an alterna-
tive media would be necessary prior to use. This additional
handling step in the clinic could be hazardous for cell
survival and iatrogenic infection, and therefore a protocol
for transportation periods longer than 24 hours requires
further optimisation.
Although the reduction in cell viability was small,
in vivo delivery of an increased number of dead cells po-
tentially has two adverse consequences: first, a reduced
efficacy; and second, the presence of dead cell debris,
which may induce inflammation. While the first conse-
quence can be compensated for by higher cell numbers,
this compounds the problems of the second.
Human MSCs stored in saline at either 4°C or room
temperature showed rapidly decreasing colony-forming
unit frequency as storage times exceeded 1 hour, despite
a population viability of over 90%, indicating that simple
measurement of viability may not fully reflect either
the self-renewal or proliferation capacity of MSCs [24].
Additionally, the differentiation potential (assessed by
trilineage differentiation) gradually decreased over time,
regardless of storage temperature, when compared withthat of freshly harvested MSCs from culture [24]. This
study therefore utilised more than one assessment of
cellular health to evaluate effects other than immediate
cell death. Other studies have reported that viability and
osteogenic potential of human MSCs were not signifi-
cantly altered by storage for 24 hours in phosphate-
buffered saline [25] and that storage of up to 6 hours in
an electrolyte solution (plasmalyte A) had no significant
adverse effect on human MSCs, as measured by viability,
differentiation capability and expression of cell surface
markers [26]. These studies suggest that a loss in differ-
entiation function is not an insurmountable, inevitable
consequence of storage or shipment. In the current
study, cells suspended in physiologic saline maintained
surprisingly good viability and high rates of proliferation
following 24 hours of storage, which is in line with pre-
viously reported, short-term viability in saline [24].
The reason for a more rapid rate of cell death in cells
suspended in BMA, in comparison with saline or
plasma, is not clear. The acellular fraction of bone mar-
row aspirate contains various growth factors and cyto-
kines, and its composition may gradually alter during
storage, with degradation of some beneficial growth fac-
tors and a gradual deterioration in quality, with a corres-
pondingly negative influence on cell viability.
The current protocol for treating clinical tendon injur-
ies involves a combination of MSCs and BMA [1,9]
although the relative contributions of each to tendon
healing have not been clarified. Maintenance of the
current protocol, which has been demonstrated to be
Figure 5 Analysis of early and late apoptosis and cell metabolic activity after injection through different gauge needles. Data are
shown for viability measured immediately after injection of mesenchymal stem cells (n =3) in D10 through 19G, 20G or 21G needles and in
non-injected controls (NI). (a) Annexin V-positive cells expressed as a percentage of the total cell population. (b) Propidium iodide-positive cells
expressed as a percentage of the total cell population. (c) Metabolic activity of mesenchymal stem cells measured by alamarBlue® (AbD Serotec,
Kidlington, UK) assay.
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on the importance of implantation within 24 hours of
dispatch, should ensure sufficient cells remain viable.
This study utilised allogeneic BMA, serum and
plasma, due to the practical and ethical difficulties in se-
curing autologous fluid from each horse for which
MSCs were available for experimental use. Future clin-
ical use of allogeneic serum-containing transport media
may necessitate heat inactivation of complement tofurther optimise cell viability. Pilot studies performed in
our laboratory suggest that heat treatment of allogeneic
plasma, bone marrow aspirate and platelet-rich plasma
(56°C for 1 hour) results in a small, but measurable,
improvement in cell viability (J. Dudhia, unpublished
observations). The particular role of complement in
cell death observed in this study is unknown and
further work should be carried out to investigate this
effect.
Figure 6 Trilineage differentiation of mesenchymal stem cells. Representative microscopic images of von Kossa and Oil-Red-O staining to confirm
osteogenic and adipogenic differentiation of plastic adherent bone marrow-derived cell populations (scale bars = 100 μm). Chondrogenic differentiation
was confirmed by the formation of dense cell pellets (haematoxylin and eosin (H&E) staining) that were positive for Safranin O (orange–red stain) (scale
bars = 1 mm). Upper row: control, non-induced cultures; central row: control, induced (non-injected) cultures. Representative images for cell populations
injected through a 23G needle and subsequently induced are shown. No difference was observed between these and populations injected through 20G
or 21G needles.
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did not have an effect on immediate cell viability, or on
differentiation potential, there were significant effects on
cellular processes. A cell damaged, but not killed, by the
process of injection could enter one of three states:
viable with a desired phenotype (that is, capable of differen-
tiation and proliferation), surviving but dysfunctional, or
apoptotic [18]. Dysfunctional cells could be further
subdivided into those that sustain mechanical stress
but remain able to restore their original capabilities,
those with permanent phenotypic change, and those
that later become apoptotic. The decrease in cell meta-
bolic activity observed immediately post injection indi-
cates that the injection process does alter cell health,
although the subsequent increase in cell metabolic ac-
tivity by 2 hours post injection suggests that the cells
have recovered their original capabilities, as shown in
other studies [18]. Although it is likely that the mech-
anism of action of MSCs in vivo involves processes
more complex and wider reaching than simple in situ
differentiation, we have demonstrated that this facility
remains intact following injection.
The proportion of early apoptotic cells present imme-
diately post injection decreased over the subsequent
24 hours. This correlates with the early stage in apop-
tosis at which externalisation of cell membrane phospha-
tidylserine residues occurs and maximum Annexin V
binding would be expected. Indeed, the time from initi-
ation of apoptosis to completion can occur in as little as
2 to 3 hours [14], which may explain the rapid decrease
in the proportion of early apoptotic cells from 4 hourspost injection. Although we did not measure caspase 3
levels or activation in the present study, analysis of this
protein in future studies may enable the apoptotic path-
ways to be consolidated in better detail.
The peak in early apoptotic cells for the 19G group
occurred at the 2-hour time point, whereas the peak
for the 21G and 23G groups was immediately post in-
jection. This observation may represent a difference in
the intensity of mechanical sheer stress between the
needle gauges, and supports previous observations that
an increase in needle diameter decreases cell damage
in human MSCs [19]. The smaller 21G and 23G nee-
dles may exert sufficient cell stress to induce apoptosis
immediately, whereas the 19G needle may induce a
lesser and more limited stress responsible for fewer
cells undergoing delayed apoptosis. Indeed, variations
in the fluid flow shear stress caused by needle walls
have been shown to induce subtle phenotypic alter-
ations and alter cell fate [27].Conclusions
We have demonstrated that, even following optimisation
of these two necessary processes, a degree of cell death
and altered cell function, albeit temporary, is to be ex-
pected. These results have implications for the efficacy
of intralesional injection of MSCs for tendon repair.
Every effort should be made to ensure that cells are
reimplanted within 24 hours of resuspension in the
laboratory and a needle with a bore larger than 21G
should be used for injection.
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